Participated · Equity · Aug 2020

Science 37 operates a decentralized clinical trial platform that coordinates telemedicine investigators and home‑health nurses to run interventional trials outside traditional clinical sites. Led by CEO David Coman, the company enables patients to participate in trials from anywhere without traveling to study sites. It closed a $40M funding round to support growth, expand its technology platform, and accelerate global expansion. The company says the new capital will strengthen its ability to help sponsors execute decentralized trials. Science 37 leverages an expansive network of clinical staff integrated with its platform to deliver decentralized trial services. The company is based in Los Angeles, CA. Science37 provides a proprietary software platform, the Network Oriented Research Assistant, that lets qualified patients access and participate in clinical trials from home using mobile devices and assigned mobile nurses. The company offers patients free tools and remote monitoring (including iPhones provided for some studies) to broaden access for those in rural areas or with scheduling constraints. Science37 is focused on studies in dermatology, oncology and headaches and also conducts trials for other research organizations. Its model has reduced recruitment time by nearly 50% in some cases, and the company sees an opportunity to increase minority representation in trials (current minority participation is cited at about 5%, with cancer trials sometimes below 2%). Planned uses of new funding include further development of the platform, expansion into new therapeutic areas, and recruiting talent from technology and clinical-trial industries to reach more diverse demographics. Science 37 is a Los Angeles-based mobile technology and clinical trial startup founded in 2014 that develops a patient-centered virtual clinical trial model. Its proprietary NORA (Network Oriented Research Assistant) platform is a cloud-based, mobile research platform that enables recruitment, electronic informed consent, patient counseling, endpoint measurement, and remote monitoring. The company replaces physical trial sites with a single "metasite™" to bring trials to patients' homes, enabling telemedicine and home visits and improving access for patients outside local site areas and those with rare diseases. Science 37 aims to reduce trial time and cost, improve recruitment and retention, and address bottlenecks in site identification and enrollment. The Series B investment will help expand operations, support further development of NORA, and enable expansion into new therapeutic areas. As part of the strategic investment, Sanofi’s international clinical trial teams will provide technical and strategic guidance. Science 37 is a Los Angeles-based technology-enabled clinical research company led by co-founder and CEO Noah Craft, MD, PhD. It is advancing a metasite operating model that delivers end-to-end clinical trial services under a single contract by leveraging partnerships with national mobile nursing companies, pharmacy chains, patient advocacy groups and other technology companies. Its technology platform, the Network Oriented Research Assistant (NORA), utilizes telemedicine and coordinates mobile workforces to overcome geographic barriers and expand access to trials, including underserved and minority populations. The company completed a $6.5M Series A financing and intends to use the funds to accelerate development and rollout of the metasite operating model. Science 37 aims to solve inefficiencies in conducting clinical trials by combining its platform with on-the-ground partners and technology integrations.